Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Woo, Jin-Hyun | - |
dc.contributor.author | Choi, Seong Jae | - |
dc.contributor.author | Ji, Jong Dae | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2021-09-08T06:13:26Z | - |
dc.date.available | 2021-09-08T06:13:26Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-01 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/117299 | - |
dc.description.abstract | The aim of this study was to assess the structural efficacies of daily glucosamine sulfate and chondroitin sulfate in patients with knee osteoarthritis (OA). The authors surveyed randomized controlled studies that examined the effects of long-term daily glucosamine sulfate and chondroitin sulfate on joint space narrowing (JSN) in knee OA patients using the Medline and the Cochrane Controlled Trials Register, and by performing manual searches. Meta-analysis was performed using a fixed effect model because no between-study heterogeneity was evident. Six studies involving 1,502 cases were included in this meta-analysis, which consisted of two studies on glucosamine sulfate and four studies on chondroitin sulfate. Glucosamine sulfate did not show a significant effect versus controls on minimum JSN over the first year of treatment (SMD 0.078, 95% CI -0.116 to -0.273, P = 0.429). However, after 3 years of treatment, glucosamine sulfate revealed a small to moderate protective effect on minimum JSN (SMD 0.432, 95% CI 0.235-0.628, P < 0.001). The same was observed for chondroitin sulfate, which had a small but significant protective effect on minimum JSN after 2 years (SMD 0.261, 95% CI 0.131-0.392, P < 0.001). This meta-analysis of available data shows that glucosamine and chondroitin sulfate may delay radiological progression of OA of the knee after daily administration for over 2 or 3 years. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER HEIDELBERG | - |
dc.subject | KNEE OSTEOARTHRITIS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | EFFICACY | - |
dc.subject | TRIALS | - |
dc.title | Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.contributor.affiliatedAuthor | Choi, Seong Jae | - |
dc.contributor.affiliatedAuthor | Song, Gwan Gyu | - |
dc.identifier.doi | 10.1007/s00296-009-0969-5 | - |
dc.identifier.scopusid | 2-s2.0-73649146195 | - |
dc.identifier.wosid | 000272869600010 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY INTERNATIONAL, v.30, no.3, pp.357 - 363 | - |
dc.relation.isPartOf | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.title | RHEUMATOLOGY INTERNATIONAL | - |
dc.citation.volume | 30 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 357 | - |
dc.citation.endPage | 363 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | KNEE OSTEOARTHRITIS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordAuthor | Glucosamine | - |
dc.subject.keywordAuthor | Chondroitin | - |
dc.subject.keywordAuthor | Knee | - |
dc.subject.keywordAuthor | Osteoarthritis | - |
dc.subject.keywordAuthor | Structural efficacy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.